論文

国際誌
2022年4月10日

Evaluation of Temozolomide Treatment for Glioblastoma Using Amide Proton Transfer Imaging and Diffusion MRI.

Cancers
  • Ryutarou Onishi
  • ,
  • Reika Sawaya
  • ,
  • Keiho Tsuji
  • ,
  • Narumi Arihara
  • ,
  • Akiko Ohki
  • ,
  • Junpei Ueda
  • ,
  • Junichi Hata
  • ,
  • Shigeyoshi Saito

14
8
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3390/cancers14081907

This study aimed to evaluate tumor changes due to chemotherapy with temozolomide (TMZ) in terms of quantitative values measured by APT imaging and NODDI. We performed TMZ treatment (administered orally by gavage to the TMZ-40 mg and TMZ-60 mg groups) on 7-week-old male Wistar rats with rat glioma C6 implanted in the right brain. T2WI, APT imaging, diffusion tensor imaging (DTI), and NODDI were performed on days 7 and 14 after implantation using 7T-MRI, and the calculated quantitative values were statistically compared. Then, HE staining was performed on brain tissue at day 7 and day 14 for each group to compare the results with the MR images. TMZ treatment inhibited tumor growth and necrotic area formation. The necrotic areas observed upon hematoxylin and eosin (HE) staining were consistent with the MTR low-signal areas observed upon APT imaging. The intracellular volume fraction (ICVF) map of the NODDI could best show the microstructure of the tumor, and its value could significantly highlight the difference in treatment effects at different TMZ doses. APT imaging and NODDI can be used to detect the microstructural changes caused by TMZ-induced tumor growth inhibition. The ICVF may be useful as a parameter for determining the effect of TMZ.

リンク情報
DOI
https://doi.org/10.3390/cancers14081907
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35454814
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031574
ID情報
  • DOI : 10.3390/cancers14081907
  • PubMed ID : 35454814
  • PubMed Central 記事ID : PMC9031574

エクスポート
BibTeX RIS